Sutro Biopharma Stock Forecast, Price & News

+0.43 (+2.35 %)
(As of 06/17/2021 04:30 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume272,657 shs
Average Volume489,850 shs
Market Capitalization$863.70 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive STRO News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Sutro Biopharma logo

About Sutro Biopharma

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.51 out of 5 stars

Medical Sector

563rd out of 2,102 stocks

Biological Products, Except Diagnostic Industry

83rd out of 198 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Sutro Biopharma (NASDAQ:STRO) Frequently Asked Questions

Is Sutro Biopharma a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Sutro Biopharma stock.
View analyst ratings for Sutro Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than Sutro Biopharma?

Wall Street analysts have given Sutro Biopharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sutro Biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Sutro Biopharma's next earnings date?

Sutro Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Sutro Biopharma

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) issued its quarterly earnings results on Thursday, May, 6th. The company reported ($0.66) EPS for the quarter, missing the Zacks' consensus estimate of ($0.62) by $0.04. Sutro Biopharma had a negative trailing twelve-month return on equity of 40.67% and a negative net margin of 85.39%.
View Sutro Biopharma's earnings history

How has Sutro Biopharma's stock been impacted by Coronavirus?

Sutro Biopharma's stock was trading at $8.11 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, STRO shares have increased by 130.9% and is now trading at $18.73.
View which stocks have been most impacted by COVID-19

What price target have analysts set for STRO?

4 equities research analysts have issued 12-month price targets for Sutro Biopharma's stock. Their forecasts range from $18.00 to $37.00. On average, they anticipate Sutro Biopharma's share price to reach $24.60 in the next twelve months. This suggests a possible upside of 31.3% from the stock's current price.
View analysts' price targets for Sutro Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Sutro Biopharma's key executives?

Sutro Biopharma's management team includes the following people:
  • Mr. William J. Newell, CEO & Director (Age 63, Pay $719.92k)
  • Dr. Trevor J. Hallam, Pres of Research & Chief Scientific Officer (Age 62, Pay $700.48k)
  • Dr. Arturo M. Molina, Chief Medical Officer (Age 62, Pay $616.76k)
  • Dr. James R. Swartz, Founder and Member of Scientific Advisory Board
  • Mr. Edward C. Albini, CFO & Sec. (Age 63)
  • Dr. Shabbir T. Anik, Chief Technical Operations Officer (Age 68)
  • Ms. Annie J. Chang, Head of Investor Relations
  • Mr. David Pauling J.D., M.A., Gen. Counsel
  • Ms. Linda A. Fitzpatrick, Chief People & Communications Officer (Age 64)
  • Dr. Nicki Vasquez, Sr. VP of Alliance Management, Portfolio Strategy & Operations

What is William J. Newell's approval rating as Sutro Biopharma's CEO?

11 employees have rated Sutro Biopharma CEO William J. Newell on William J. Newell has an approval rating of 100% among Sutro Biopharma's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Sutro Biopharma's key competitors?

What other stocks do shareholders of Sutro Biopharma own?

When did Sutro Biopharma IPO?

(STRO) raised $75 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Sutro Biopharma's stock symbol?

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

Who are Sutro Biopharma's major shareholders?

Sutro Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.73%), Franklin Resources Inc. (5.74%), First Light Asset Management LLC (4.46%), Holocene Advisors LP (3.09%), Loomis Sayles & Co. L P (2.94%) and Suvretta Capital Management LLC (2.79%). Company insiders that own Sutro Biopharma stock include Arturo Md Molina, John Gordon Freund, Trevor Hallam and William J Newell.
View institutional ownership trends for Sutro Biopharma

Which major investors are selling Sutro Biopharma stock?

STRO stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Point72 Asset Management L.P., Tekla Capital Management LLC, Pentwater Capital Management LP, Schonfeld Strategic Advisors LLC, Parkman Healthcare Partners LLC, Goldman Sachs Group Inc., and D. E. Shaw & Co. Inc.. Company insiders that have sold Sutro Biopharma company stock in the last year include John Gordon Freund, and Trevor Hallam.
View insider buying and selling activity for Sutro Biopharma
or view top insider-selling stocks.

Which major investors are buying Sutro Biopharma stock?

STRO stock was acquired by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, First Light Asset Management LLC, Morgan Stanley, Franklin Resources Inc., BlackRock Inc., Holocene Advisors LP, Compagnie Lombard Odier SCmA, and Dimensional Fund Advisors LP. Company insiders that have bought Sutro Biopharma stock in the last two years include Arturo Md Molina, and William J Newell.
View insider buying and selling activity for Sutro Biopharma
or or view top insider-buying stocks.

How do I buy shares of Sutro Biopharma?

Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sutro Biopharma's stock price today?

One share of STRO stock can currently be purchased for approximately $18.73.

How much money does Sutro Biopharma make?

Sutro Biopharma has a market capitalization of $863.70 million and generates $42.72 million in revenue each year. The company earns $-32,130,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis.

How many employees does Sutro Biopharma have?

Sutro Biopharma employs 195 workers across the globe.

What is Sutro Biopharma's official website?

The official website for Sutro Biopharma is

Where are Sutro Biopharma's headquarters?

Sutro Biopharma is headquartered at 310 Utah Avenue Suite 150, South San Francisco CA, 94080.

How can I contact Sutro Biopharma?

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company can be reached via phone at 650-392-8412 or via email at [email protected]

This page was last updated on 6/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.